Immuno-Oncology Conference 2018

SMi Group26 - 27 September, London, UK.
Immuno-Oncology is a fast-paced field with massive potential to deliver successful and durable cancer therapies. SMi's Immuno-Oncology Conference will focus on a few key areas of the field with representation of the whole industry, under each area. These areas will be drawn together to look towards the future of Immuno-oncology and how the field can progress.

Agenda - Over 15 engaging presentations, case studies, keynote addresses, including:

  • Targeting immune checkpoints with Humabody VH therapeutics
  • Recent advances in providing durable disease control with Keytruda as an anti-cancer therapy
  • Tumour mutation burden and the potential of its use as an indication of treatment choice
  • Unwanted immunogenicity and functionality testing of immuno-oncology drugs
  • New techniques, such as the emerging applications of liquid biopsies, in Immuno-Oncology

Speakers - Over 15 leading experts in Immuno-Oncology field, including:

  • James Legg, Vice President R&D, Crescendo Biologics
  • Andrew Exley, Medical Assessor, MHRA
  • Harry Smith, Medical Scientist, Gilead Sciences
  • Grace Macaulay, Global Safety Physician Patient Safety Oncology, MedImmune
  • David Giljohan, CEO, Exicure
  • KandeepanGaneshalingam, Executive Director, Oncology Therapeutic Area Head, European Clinical Development, MSD
  • RochanaWickramasinghe, Director of Oncology Evaluation, AstraZeneca

Workshops - Carefully selected topics for further on-sight training. 2 pre-conference workshops (25 September) to provide in-depth knowledge on specific topics:

  • Strategic Competitive Intelligence in the Immuno-Oncology space - hosted by LucidQuest Ventures
  • Could the Microbiome boost Cancer Immuno-Therapy - hosted by ImmuneBiotech and Lund University

Networking - it is at the forefront of SMi events. 5+ hours of pure networking guaranteed. Follow event updates to be in the know about who will be joining the conversation.

For further details, please visit:
http://www.immuno-oncology-conference.com

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Most Popular Now

FDA highlights record-breaking number of generic d…

Today, the U.S. Food and Drug Administration is providing a summary of the generic drug approval actions for the month of October 2018 as part of its efforts to improve p...

FDA approves new drug to treat influenza

The U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older...

Novartis announces clinical collaboration with Pfi…

Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer comp...

Alcon to develop SMART Suite digital health platfo…

Alcon, the global leader in eye care and a division of Novartis, today announced plans to develop the SMART Suite by Alcon, an innovative, digital platform that is design...

Twenty years on, measuring the impact of human ste…

In November 1998, the world was introduced to human embryonic stem cells, the blank slate cells that arise at the earliest stages of development and that go on to become ...

Novartis R&D update highlights industry leadin…

Throughout 2018, Novartis took strong action to focus the company and its capital towards the Innovative Medicines Division, resulting in an industry leading pipeline. To...

Boehringer Ingelheim inaugurates new centre for ag…

Boehringer Ingelheim has taken an important step towards greater agility in the company with inauguration of the new building, called "BI CUBE", at the Ingelheim site. Th...

New epigenetic drug strategy to treat cancer

Researchers have discovered that inhibiting CDK9, a DNA transcription regulator, reactivates genes that have been epigenetically silenced by cancer. Reactivation leads to...

Largest census of cancer genes to help understand …

Researchers at the Wellcome Sanger Institute have created the first comprehensive summary of all genes known to be involved in human cancer, the "Cancer Gene Census". Des...

FDA approves asthma indication for Dupixent® (dupi…

The U.S. Food and Drug Administration has approved Dupixent® (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and old...

Can chocolate, tea, coffee and zinc help make you …

Ageing and a low life expectancy are caused, at least partly, by oxidative stress. A team of researchers led by Prof. Dr. Ivana Ivanovi-Burmazovi from the Chair of Bioino...

Agreement with Grünenthal for rights to Nexium in …

AstraZeneca has agreed to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo ...